Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz haqimizda

Biz bilan bog'lanish

[email protected]

Bizni kuzating

Instagram
Telegram
LinkedIn

Barcha huquqlar himoyalangan.

Foydalanish shartlari

Bosh sahifa
Bozorlar
Skriner
Yangiliklar
Biz haqimizda

EVH - Evolent Health, Inc. So'nggi Yangiliklar | Finranks

Home

EVH

(EVH)

NYQ – Real vaqt narxi. Valyuta: USD

2.21

-0.17 (-7.14%)

Yopilishda: Mar 27, 2026, 4:00 PM EDT

2.22

+0.01 (0.45%)

Bozordan keyin: Mar 27, 2026, 7:57 PM EDT

Umumiy
Yangiliklar
Grafik
Hisobotlar
Dividendlar
Kutilma
Egalik
Profil

Evolent announces appointment of Archie Mayani as chief product officer

Evolent announces appointment of Archie Mayani as chief product officer

Industry veteran brings track record of innovation from GHX, Change Healthcare, UnitedHealth Group and Amazon. WASHINGTON, March 19, 2026 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH), a company focused on achieving better health outcomes for people with complex conditions, today announced the appointment of health care technology leader and AI innovator Archie Mayani as chief product officer (CPO).

Evolent to Participate in Upcoming Investor Conferences

Evolent to Participate in Upcoming Investor Conferences

WASHINGTON, Feb. 26, 2026 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH), a company focused on achieving better health outcomes for people with complex conditions, today announced that members of its executive management team will participate in upcoming investor conferences. A live audio-only webcast and replay for these events will be available on the "Events and Presentations" section of Evolent's investor relations website.

Evolent Health: Cheap, Levered, But Ready To Rebound

Evolent Health: Cheap, Levered, But Ready To Rebound

Evolent Health, Inc. is rated a Buy, with turnaround momentum and risk/reward now favoring upside after recent operational and strategic shifts. EVH's Performance Suite model now covers ~90% of revenue, offering risk protection and greater earnings predictability, despite near-term profit headwinds from new contract launches. Oncology drives EVH's growth, with strong customer retention (>98%) and cost discipline via AI automation and workforce efficiencies delivering $20M+ in annualized savings.

Evolent Health, Inc. (EVH) Q4 2025 Earnings Call Transcript

Evolent Health, Inc. (EVH) Q4 2025 Earnings Call Transcript

Evolent Health, Inc. (EVH) Q4 2025 Earnings Call Transcript

Compared to Estimates, Evolent Health (EVH) Q4 Earnings: A Look at Key Metrics

Compared to Estimates, Evolent Health (EVH) Q4 Earnings: A Look at Key Metrics

While the top- and bottom-line numbers for Evolent Health (EVH) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Evolent Health (EVH) Q4 Earnings Top Estimates

Evolent Health (EVH) Q4 Earnings Top Estimates

Evolent Health (EVH) came out with quarterly earnings of $0.08 per share, beating the Zacks Consensus Estimate of $0.06 per share. This compares to a loss of $0.02 per share a year ago.

Evolent Announces Fourth Quarter 2025 Results and Full Year 2025 Results

Evolent Announces Fourth Quarter 2025 Results and Full Year 2025 Results

WASHINGTON, Feb. 24, 2026 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH) ("Evolent" or the "Company"), a company that specializes in better health outcomes for people with complex conditions through proven solutions that make health care simpler and more affordable, today announced financial results for the three months ended December 31, 2025. Seth Blackley, Co-Founder and Chief Executive Officer of Evolent stated, "In 2025 we executed on our earnings targets, continued to grow market share, renewed customers at strong rates, and continued the migration of Performance Suite clients to our enhanced Performance Suite contract model.

Videolar

No Data

There is no data to display